Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia.

ABSTRACT: Accumulating evidence of glutamatergic abnormalities in the brains of schizophrenia patients has led to efforts to target various components of glutamatergic signaling as potential new approaches for schizophrenia. Exciting research suggests that metabotropic glutamate (mGlu) receptors could provide a fundamentally new approach for better symptomatic relief in patients with schizophrenia. In preclinical studies, the mGlu₅ receptor positive allosteric modulators (PAMs) show efficacy in animal models relevant for all symptom domains in schizophrenia. Interestingly, biased pure mGlu₅ receptor PAMs that do not potentiate coupling of mGlu₅ receptors to N-methyl-D-aspartate (NMDA) receptors lack neurotoxic effects associated with mGlu₅ PAMs that enhanc

SUBMITTER: Dogra S 

PROVIDER: S-EPMC9092465 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature